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Edaravone (5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one, EDV) is a free-radical scavenger reduces organ ischemic injury.
Here we investigated whether the protective effects of EDV in renal ischemia/reperfusion (I/R) injury may be enhanced by
an EDV derivative bearing a nitric oxide- (NO-) donor furoxan moiety (NO-EDV). Male Wistar rats were subjected to renal
ischemia (45minutes), followed by reperfusion (6 hours). Administration of either EDV (1.2–6–30 𝜇mol/kg, i.v.) or NO-EDV (0.3–
1.2–6 𝜇mol/kg, i.v.) dose-dependently attenuated markers of renal dysfunction (serum urea and creatinine, creatinine clearance,
urine flow, urinary N-acetyl-𝛽-D-glucosaminidase, and neutrophil gelatinase-associated lipocalin/lipocalin-2). NO-EDV exerted
protective effects in the dose-range 1.2–6 𝜇mol/kg, while a higher dose (30 𝜇mol/kg) was needed to obtain protection by EDV.
Both EDV and NO-EDV modulated tissue markers of oxidative stress and lipid peroxidation. NO-EDV, but not EDV, activated
endothelial NO synthase (NOS) and blunted I/R-induced upregulation of inducible NOS, secondary to modulation of Akt and NF-
𝜅B activation, respectively. Besides NO-EDV administration inhibited I/R-induced IL-1𝛽, IL-18, IL-6, and TNF-𝛼 overproduction.
Overall, these findings demonstrate that the NO-donor moiety contributes to the protection against early renal I/R injury and
suggest that NO-donor EDV codrugs are worthy of additional study as innovative pharmacological tools.
1. Introduction
Edaravone (5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-
3-one, EDV, Figure 1(a)) is a novel free-radical scavenger,
which reacts with free radicals by a one-electron transfer
mechanism in polar media, whereas the mechanism of H-
atom abstraction has been hypothesized to be predominant
in lipid phase [1]. EDV has been approved as neuroprotective
agent for the treatment of acute brain infarction by the
Japanese Health Organization since 2001 [2]. Moreover, EDV
exerts protective effects in patients with acute myocardial
infarction [3]. Cases of patientswith strokewhounexpectedly
developed acute kidney injury (AKI) during EDV
administration have been previously reported [4]. However,
most recent clinical evidence identifies EDV as a protective
factor for the development of AKI [5]. This is in keeping
with previous experimental studies showing that EDV
exerted protective effects against the occurrence of kidney
injury caused by renal ischemia/reperfusion (I/R) [6, 7]
and cisplatin administration [8, 9]. Ischemic AKI is an
important challenge for clinicians, as it is present in 2% of
all hospitalized patients, up to 40% of intensive care unit
patients, with a mortality rate >50% in dialyzed patients [10].
Besides, there is currently no successful therapy that can
attenuate kidney injury or expedite recovery; thus treatment
is only supportive. The etiology of renal ischemic injury is
complex and reperfusion, although being essential for the
survival of the ischemic kidney, may cause additional injury
[11]. Several experimental evidences suggest that nitric oxide
(NO) pathway exerts a crucial role in the regulation of renal
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Figure 1: Chemical structures of edaravone (EDV) and edaravone derivative containing NO-donor furoxan moiety (NO-EDV).
hemodynamics and function [12]. During ischemia NO
protects the ischemic tissue due to its vasodilatatory action.
In the reoxygenation phase, NO can react with superoxide
radicals, impeding the chain of reaction for additional
production of reactive oxygen species (ROS), such as
hydrogen peroxide and hydroxyl radical, and thus reducing
leukocyte activation and the formation of inflammatory
mediators [13]. However, overproduction of NO can be
deleterious due to its ability to generate peroxynitrite, which
can cause lipid peroxidation of cell membranes.
In this study we investigated the hypothesis that the
protective effects of EDV in the early phase of renal I/R may
be enhanced by using an EDVderivative bearing aNO-donor
furoxan moiety (4-{[4-(3-methyl-5-oxo-4,5-dihydro-1H-
pyrazol-1-yl)phenoxy]methyl}-furoxan-3-carboxamide, NO-
EDV, Figure 1(b)). NO-EDV has been recently synthesized
and characterized by members of our research team within
an extended study of NO-donor antioxidant hybrid drugs
[14, 15]. The release of NO by NO-EDV was about 14%
with respect to the concentration of furoxan after 2 h of
incubation with a strong excess of cysteine and studies by
electron paramagnetic resonance have demonstrated that the
species formed during furoxan ring opening is NO radical.
This hybrid compound has been selected for the present
study in view of its good balance between antioxidant and
vasodilator properties. Specifically, this hybrid drug has been
demonstrated to exert potent antioxidant activity, mainly
due to the edaravone substructure, and robust vasodilator
activity, which parallels that of the corresponding reference
simple NO-donor [16]. To gain a better understanding of the
effects of EDV in comparison to the related EDV derivative
containing the NO-donor function, we carried out further
investigation on the role of the NO signaling pathway.
2. Materials and Methods
2.1. Animals and Surgery. Male Wistar rats (Harlan-Italy;
Udine, Italy) were fed with a Piccioni pellet diet (n. 48,
Gessate Milanese, Italy) and water ad libitum. Animal care
was in compliance with Italian regulations on the protection
of animals used for experimental and other scientific pur-
poses (D.M. 116/92) as well as the Guide for the Care and
Use of Laboratory Animals as adopted and promulgated
by the US National Institutes of Health. The renal I/R
protocol described here has been approved by the Turin
University Ethics Committee and it was employed inmultiple
previous reports from our laboratory, resulting in significant
reproducible and severe (but not fatal) renal dysfunction and
injury [17–19]. Briefly, the rats were anesthetized through
i.p. injection (30mg/kg) of Zoletil (15mg/kg tiletamine +
15mg/kg zolazepam; Zoletil 100, 100mg/mL, Laboratoires
Virbac, France). The anesthetized rats were placed onto a
thermostatically controlled heating pad, a rectal temperature
probe was inserted, and body temperature was monitored
and maintained at 37∘C. A midline laparotomy was per-
formed and the bladder was cannulated for the collection
of urine. The kidneys were located and the renal pedicles,
containing the renal artery, vein, and nerves, were carefully
isolated. The rats were subjected to bilateral renal occlusion
for 45min using nontraumatic artery clamps (Dieffenbach
BulldogClamps,HarvardApparatus Ltd., Kent, UK) to clamp
the renal pedicles, followed by reperfusion for 6 h. Sham-
operated rats underwent identical surgical procedures to
those undergoing I/R except that artery clamps were not
applied. At the end of the reperfusion, the anaesthetized
rats were killed by an overdose of anesthetic, after aortic
exsanguination. The kidneys were isolated, weighed, rapidly
freeze-clamped with liquid nitrogen, and stored at −80∘C
until being needed.
2.2. Drugs and Treatments. EDV (MW 174Da) was dissolved
in DMSO/propylene glycol/saline solution (5%/20%/75%,
resp.) and administered (1.2–6–30𝜇mol/kg, i.v.) at the begin-
ning of reperfusion and again after 30min reperfusion. The
kinetics and the dose-range were based on those previously
shown to ameliorate I/R injury in the rat kidney [20, 21].
NO-EDV (MW 331Da) was dissolved in DMSO/propylene
glycol/saline solution (5%/20%/75%, resp.) and administered
(0.3–1.2–6 𝜇mol/kg, i.v.) at the beginning of reperfusion
and again after 30min reperfusion. The NO-EDV dose
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stoichiometric equivalent to 30𝜇mol/kg EDV could not be
used because of limited solubility of NO-EDV in the vehicle.
Animals were randomly assigned to the following exper-
imental groups:
(i) sham: rats were treated with the vehicle and subjected
to the surgical procedure alone, without causing
ischemia (𝑛 = 8);
(ii) IR: rats were subjected to 45min ischemia followed
by 6 h reperfusion and treated with the vehicle, at
the beginning of reperfusion and again after 30min
reperfusion (𝑛 = 8);
(iii) IR + EDV: rats were subjected to 45min ischemia
followed by 6 h reperfusion and treated with EDV
(0.3–1.2–6 𝜇mol/kg), at the beginning of reperfusion
and again after 30min reperfusion (𝑛 = 8);
(iv) IR +NO-EDV: rats were subjected to 45min ischemia
followed by 6 h reperfusion and treated with NO-
EDV (i.v.), at the beginning of reperfusion and again
after 30min reperfusion (𝑛 = 8).
2.3. Measurement of Biochemical Parameters. At the end of
the reperfusion period, 1mL blood samples were collected
and centrifuged (10,000 g for 10min) to separate the serum,
from which biochemical parameters were measured within
24 h. The volume of urine produced was determined using
the urine collected during the reperfusion period. Serum and
urine creatinine concentrations were measured spectropho-
tometrically at 490 nm by the Jaffe´ kinetic reaction, using
commercially available kits. Renal creatinine clearance was
calculated by the standard formula 𝐶 = (𝑈 × 𝑉)/𝑆, where
𝑈 is the concentration in urine, 𝑉 is urine flow rate, and
𝑆 is the serum concentration. Serum urea and creatinine
concentrations and creatinine clearance were used as indi-
cators of impaired renal function. Neutrophil gelatinase
associated lipocalin/lipocalin-2 (NGAL) and N-acetyl-𝛽-
glucosaminidase (NAG) were measured in the urine using
commercial enzyme-linked immunosorbent assay (ELISA)
kits (MyBiosource, San Diego, CA, USA), and were used as
early, sensitive biomarkers for ischemic renal injury [22, 23].
2.4. Histopathological Examination and Tissue Injury Scoring.
Coronal sections of both kidneys were overnight fixed in 4%
buffered formaldehyde solution. Histological examination
on PAS stained sections were performed to evaluate the
following parameters of tubular cell injury: loss of brush
border (LBB: partial or complete loss of the brush border),
vacuolar degeneration (vac. deg.: presence of more than
three cells with cytoplasmic vacuoles or blebs formation
protruding into the lumen of the tubules), tubular dilatation
(tub. dil.: dilatation was considered when the tubular lumen
was increased at least 20% versus normal corespective), cell
detachment (cell det.: presence of necrotic or morphological
well preserved isolated cells in the tubular lumen), necrosis
(necrosis: presence of three or more cells with signs of
coagulative necrosis, such as loss of cell boundaries with
marked eosinophilia or extreme swelling together with
nuclear changes consisting in pyknosis or chromatolysis or
karyorrhexis), and formation of casts (casts: presence of
granule-hyaline, mucous or proteinaceous material in the
tubular lumen). Five nonconsecutive fields from the cortex
and the outer medulla were evaluated (magnification 200x).
Renal injury scores were determined by the percentage of
tubules involved: 0 = 0; 1 = up to 10%; 2 = 11–20%; 3 = 21–40%;
4 = 41–60%; 5 = more than 61%.
2.5. Western Blot Analysis. Western blots were carried out as
previously described [24]. Briefly, rat kidney samples were
homogenized in 10% homogenization buffer and centrifuged
at 1,300 g for 5 minutes at 4∘C. Supernatants were removed
and centrifuged at 16,000 g at 4∘C for 40minutes to obtain the
cytosolic fraction. The pelleted nuclei were resuspended in
extraction buffer and centrifuged at 16,000 g for 20minutes at
4∘C. The resulting supernatants containing nuclear proteins
were carefully removed, and protein content was determined
on both nuclear and cytosolic extracts using a bicinchoninic
acid (BCA) protein assay following the manufacturer’s direc-
tions (Thermo Fisher Scientific, Runcorn, UK). Proteins were
separated by 8% sodium dodecyl sulphate-polyacrylamide
gel electrophoresis and transferred to polyvinyldenediflu-
oride membrane, which was then incubated with a pri-
mary antibody (rabbit anti-iNOS, mouse anti-phAkt, rabbit
anti Akt, goat anti-ph-eNOS, rabbit anti-eNOS, and rabbit
anti-MnSOD). Blots were then incubated with a secondary
antibody conjugated with horseradish peroxidase (dilution
1 : 10000) and developed using the ECL detection system.The
immunoreactive bands were visualized by autoradiography
and the density of the bands was evaluated densitometrically
using Gel Pro Analyzer 4.5, 2000 software (Media Cybernet-
ics, Silver Spring, MD, USA). The membranes were stripped
and incubated with 𝛽-actin monoclonal antibody (dilution
1 : 5000) and subsequently with an anti-mouse antibody
(dilution 1 : 10000) to assess gel-loading homogeneity.
2.6. Determination of Malondialdehyde (MDA) Levels. MDA
levels were determined in the supernatant fractions of kidney
homogenized samples by high-performance liquid chro-
matography (HPLC) system (Shimadzu VP Class, Shimadzu
Corporation, Japan)with fluorescence detection using a com-
mercial reagent kit (Chromsystems Instruments & Chem-
icals, Gra¨felfing, Germany), as previously described [25].
Measurements were expressed in terms of MDA normalized
to the tissue protein content.
2.7. Determination of Interleukin- (IL-) 1𝛽, IL-6, IL-18, and
Tumor Necrosis Factor- (TNF-) 𝛼 Production. Cytokines were
measured in kidney homogenates using commercial ELISA
kits (Cayman Chemical, Ann Arbor, MI), following the
protocol provided by the manufacturer.
2.8. Materials. Unless otherwise stated, all compounds were
purchased from Sigma-Aldrich Company Ltd. (Missouri,
USA). The BCA Protein Assay Kit and SuperBlock block-
ing buffer were from Pierce Biotechnology Inc. (Illinois,
USA). Antibodies were from Cell Signaling Technology
(Massachusetts, USA). Luminol ECL was from Amersham
(Buckinghamshire, UK).
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2.9. Statistical Analysis. All values in both the text and
figures are expressed as mean ± standard error of the mean
(S.E.M.) for 𝑛 observations. One-way analysis of variance
with Dunnett’s posttest was performed using the GraphPad
Prism Software (San Diego, California, USA) and 𝑃 values
below 0.05 were considered as significant.
3. Results
3.1. Comparative Effects of Acute Administration of EDV
and NO-EDV on I/R-Induced Renal Dysfunction. Rats that
underwent renal I/R exhibited a significant increase in serum
levels of urea and creatinine, compared with sham-operated
rats (Figures 2(a) and 2(b), resp.), suggesting a significant
degree of renal dysfunction. To discount the possibility of
a rapid increase in serum creatinine levels due to increased
release of creatinine from muscle during I/R, creatinine
clearance was also measured. I/R exposure led to a drastic
decrease in creatinine clearance (Figure 2(c)) as well as in
urine flow (Figure 2(d)). Administration of EDV significantly
attenuated the injury and glomerular dysfunction caused by
I/R when tested at the highest dose (30 𝜇mol/kg), with no
effects at the doses 1.2 and 6 𝜇mol/kg. Interestingly, NO-EDV
evoked a robust improvement in renal function at the doses
1.2 and 6 𝜇mol/kg, which are stoichiometrically equivalent to
the noneffective doses of EDV. As shown in Figures 2(e) and
2(f), renal I/R induced a significant increase in urinaryNGAL
and NAG levels, suggesting significant tubular dysfunction,
which was reduced in a dose-dependent way by both EDV
and NO-EDV. Notably, whereas EDV was ineffective in the
dose-range 1.2 and 6 𝜇mol/kg, the stoichiometric equivalent
dose-range of NO-EDV exerted significant protective effects.
3.2. Effects of EDV and NO-EDV on the Morphological
Alterations Associated to I/R Injury. Representative pictures
from each experimental groupwere taken from the transition
between the deeper cortex and the outer stripe of the
outer medulla zones (Figure 3(a): ×200; PAS stained. G:
glomerulus. PT: proximal tubules). When compared against
the kidney from the sham group, where the cells of the
PT appeared morphologically normal with a well preserved
brush border and nuclei polarized against the basal mem-
brane, the major part of the PT from the ischemically injured
kidney was mainly composed of coagulated necrotic cells
with abundant cell debris occupying the lumen of the tubules.
Interestingly after the treatment with EDV (30 𝜇mol/kg) and
NO-EDV (6 𝜇mol/kg) the amount of severely damaged and
necrotic cells within PTs was significantly decreased. At the
same time, many PTs were composed of cells that exhibited
a partial preservation of the brush border, as well as the
maintenance of the nuclear polarization. The reduction in
these renal abnormalities was still evident when animals
were treated with NO-EDV at the lowest dose (1.2 𝜇mol/kg).
Semiquantitative scoring of kidney injury performed on the
histological slides confirmed the visual observations and
showed that both EDV andNO-EDV significantly attenuated
renal cell damage (Figure 3(b)).
3.3. Effects of EDV and NO-EDV on Oxidative Stress Induced
by Renal I/R Injury. Compared to sham-operated rats, kid-
neys obtained from rats that had undergone I/R exhibited
a massive increase in MDA levels, an indicator of lipid
peroxidation (Figure 4(a)). The robust increase in lipid per-
oxidation was blunted by administration of EDV in a dose-
dependent manner and partially prevented by NO-EDV at
the highest dose tested here (6𝜇mol/kg). Simultaneously, the
expression of the endogenous antioxidant enzyme MnSOD
(Figure 4(b)) was upregulated following EDV administration
during reperfusion, with maximum effect at 30𝜇mol/kg. A
slight increase inMnSOD expressionwas also recorded in the
group treated with the highest dose of NO-EDV.
3.4. Effects of Drug Treatments on Akt and eNOS Phospho-
rylation in the Kidneys of Rats That Underwent I/R Injury.
The degree of the phosphorylation of Akt on Ser473 and
eNOS on Ser1177 in reperfused kidney samples was similar
in sham-operated rats and I/R rats, indicating that I/R alone
is not sufficient to affect this signaling pathway (Figures 5(a)
and 5(b)). Similarly, Akt and eNOS phosphorylation levels
were not modified by EDV administration. In contrast, acute
administration of NO-EDV (1.2 and 6 𝜇mol/kg) evoked a
significant increase in the phosphorylation of Akt and eNOS,
suggestive of an increased enzyme activation (Figures 5(a)
and 5(b)).
3.5. NO-EDV, but Not EDV, Inhibited iNOS Expression, NF-𝜅B
Nuclear Translocation, and Cytokine Production Evoked by I/R
Injury. When the expression levels of the iNOS isoformwere
measured (Figure 6(a)), we detected low protein expression
in the kidney of sham-operated animals. I/R injury induced
a robust increase in the expression of iNOS, which was
not further modified by EDV administration. In contrast,
rats treated with NO-EDV during reperfusion showed a
significant decrease in iNOS overexpression induced by I/R.
When compared with sham-operated rats, the kidneys of
I/R rats treated with vehicle exhibited significant increases
in the nuclear translocation of the p65 NF-𝜅B subunit
(Figure 6(b)), indicating the activation of NF-𝜅B. NO-EDV
administration resulted in a significant reduction in nuclear
translocation of p65 and, hence, in the activation of NF-
𝜅B in the kidney. This effect was not recorded when I/R
rats were treated with the stoichiometrically equivalent dose
of EDV (6 𝜇mol/kg), not even when rats were exposed
to the highest dose (30𝜇mol/kg). TNF-𝛼, IL-6, IL-1𝛽, and
IL-18, typical proinflammatory cytokines, were significantly
increased in kidney homogenates from rats exposed to
I/R injury, as compared with the sham-operated animals
(Figure 7). Interestingly, administration of NO-EDV, but not
EDV, reported cytokines concentration back to values similar
to those measured in the kidneys of sham-operated animals
in a dose-dependent manner.
4. Discussion
Our results further corroborate and extend previous findings
demonstrating that EDV exerts beneficial effects against
organ ischemic damage, including renal I/R [26–30]. Here we
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Figure 2: Effects of EDV and NO-EDV on renal dysfunction evaluated on blood and urine parameters. Serum urea (a), creatinine (b),
creatinine clearance (c), urine flow (d), and urinary NGAL (e) and NAG (f) levels were measured after sham operation (sham) or renal
ischemia-reperfusion injury (vehicle). Further groups of rats received EDV (1.2–30 𝜇mol/kg, i.v.) or NO-EDV (0.3–6 𝜇mol/kg, i.v.) at the
beginning of reperfusion and again after 30min reperfusion. Data are expressed as mean ± S.E.M. ∗𝑃 < 0.05 versus vehicle.
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Figure 3: Effects of EDV and NO-EDV on the I/R injured kidney. (a) Representative pictures from the different groups. (b) Semiquantitative
assessment of the severity of kidney damage. Histological examination of both kidneys to detect loss of brush border (LBB), cell detachment
(cell det.), necrosis (necrosis), formation of casts (casts), and tubular dilatation (tub. dil.) was performed on PAS stained sections. Five
nonconsecutive fields from the cortex and the outer medulla were evaluated (magnification 200x). Renal injury scores were determined
by the percentage of tubules involved: 0 = 0; 1 = up to 10%; 2 = 11–20%; 3 = 21–40%; 4 = 41–60%, and 5 = more than 61%. G: glomeruli; PT:
proximal tubules; green arrowhead: preserved brush border; green arrow: nuclei polarized against the basal membrane; green star: cell debris;
green cross indicates hyaline casts. Data are expressed as mean ± S.E.M. ∗𝑃 < 0.01 versus vehicle.
showed that acute administration of EDV during reperfusion
affected earlymarkers of renal dysfunction and injury evoked
by I/R, including reduction in serum creatinine and urea
and increases in creatinine clearance and urine flow. Tubular
protection is suggested by a significant reduction in urinary
excretion of both NAG and NGAL, well-known markers of
tubular cell dysfunction. These effects were associated with
a significant reduction of local lipid peroxidation as well as
an increased expression of the antioxidant enzyme MnSOD.
These data are compelling in light of a recent clinical study
suggesting that EDV may be a useful medication to protect
the kidney function in patients with acute ischemic stroke [5].
Overall, our findings are congruent with recently published
data indicating that I/R-induced kidney damage occurs very
early, already during the first hours of reperfusion injury, and
can be significantly alleviated by an early intervention, which
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Figure 4: Effects of EDV and NO-EDV on markers of oxidative stress in kidney samples. MDA levels (a) and MnSOD expression (b) were
measured subsequent to sham operation (sham) or renal ischemia-reperfusion injury in the absence (vehicle) or presence of EDV (1.2–
30 𝜇mol/kg, i.v.) or NO-EDV (0.3–6 𝜇mol/kg, i.v.). Data are expressed as mean ± S.E.M. ∗𝑃 < 0.05 versus vehicle.
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Figure 5: Effects of EDV and NO-EDV on Akt and eNOS phosphorylation. Representative Western blot and corresponding densitometric
analysis of the bands showing phosphorylated (Ser473) and total Akt (panel (a)) and phosphorylated (Ser1177) and total eNOS in rats exposed
to I/R in the absence (vehicle) or presence of EDV (6 and 30 𝜇mol/kg, i.v.) or NO-EDV (1.2 and 6 𝜇mol/kg, i.v.). Each immunoblot is from a
single experiment and is representative of three separate experiments. Densitometric analysis of the related bands is expressed as relative OD,
corrected for the corresponding 𝛽-actin contents, and normalized using the related sham-operated band.The data from bands densitometric
analysis are mean S.E.M. ∗𝑃 < 0.05 versus vehicle.
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Figure 6: Effects of EDV and NO-EDV on iNOS expression and p65 NF-𝜅B nuclear translocation. Representative Western blot and
corresponding densitometric analysis of the bands showing iNOS protein expression (panel (a)) and NF-𝜅B p65 subunit translocation from
the cytosol to the nucleus (panel (b)) were evaluated in the kidney homogenates of rats subjected to the surgical procedure alone (sham) or
rats subjected to I/R treated with vehicle or EDV (6 and 30 𝜇mol/kg, i.v.) or NO-EDV (1.2 and 6 𝜇mol/kg, i.v.). Each immunoblot is from a
single experiment and is representative of three separate experiments. Densitometric analysis of the related bands is expressed as relative OD,
corrected for the corresponding 𝛽-actin contents, and normalized using the related sham-operated band.The data from bands densitometric
analysis are mean S.E.M. ∗𝑃 < 0.05 versus vehicle.
not only can be beneficial in terms of the acute alterations
but may also have positive impact on the long-term effects of
renal damage [31–33].
Although the molecular mechanisms underlying the I/R-
induced renal injury are yet poorly understood, several
causal factors (including ATP depletion, ROS production,
and leukocyte activation) have been shown to contribute to its
pathogenesis [34]. A key role in the homeostasis of the renal
hemodynamic and function is exerted by the soluble gas NO.
Decreased NO bioavailability is accompanied by endothelial
cell dysfunction and impaired renal microcirculation [35, 36]
and changes in NO production in the kidney are closely
related to various pathological conditions, such as chronic
renal failure, lipopolysaccharide-induced renal dysfunction,
and AKI [37, 38]. Accordingly, several studies have demon-
strated that endogenous or exogenousNOprotects the kidney
against I/R injury [39–41]. In keeping with these evidences,
we demonstrated here for the first time that the acute
administration of an EDV derivative containing NO-donor
function caused a pronounced reduction in early markers of
renal I/R injury and dysfunction, similar to the one afforded
by EDV. The limited solubility of NO-EDV in the vehicle
did not allow a direct comparison at the same stoichiometric
equivalent highest dose (30 𝜇mol/kg). Nevertheless, it is
noteworthy that protective effects by NO-EDVwere detected
in the dose-range 1.2–6𝜇mol/kg, while the stoichiometric
equivalent doses of EDV showed no effect and a higher dose
(30 𝜇mol/kg) was needed to obtain protection by EDV.Thus,
it appears that theNO-donormoiety significantly contributes
to counteract the renal I/R injury, leading to obtaining protec-
tive effects at doses lower than those required by EDV alone.
This increased efficacy is due, at least in part, to the activation
of additive protective intracellular mechanisms by the NO-
donor substructure. For instance, NO-EDV caused a robust
increase in phosphorylation of specific serine residues in Akt,
whichwas not recordedwhen animalswere treatedwith EDV.
Akt is a member of the phosphoinositide 3-kinase signal
transduction enzyme family which, upon phosphorylation
by its upstream regulator, can promote eNOS activation
and exert several anti-inflammatory and antiapoptotic effects
[42]. A reduction in the activation of this important survival
pathway has been recently demonstrated to make the kidney
more susceptive to I/R insult [43, 44]. Here we show that the
increase in Akt phosphorylation was associated with massive
eNOS, activation, thus resulting in an enhanced formation
of NO in the microcirculation. The enhanced activation
of eNOS (possibly secondary to activation of Akt) should
make the kidney of animals treated with NO-EDV more
resistant to injury. Our results are corroborated by other
studies demonstrating that NO generated by constitutive
eNOS is beneficial and mechanisms that increase eNOS
activity protect against renal I/R injury [45–48]. In contrast,
the role of iNOS in renal I/R injury remains controversial.
Some studies have demonstrated that renal I/R injury was
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Figure 7: Effects of EDV and NO-EDV on cytokine production in kidney samples. TNF-𝛼 (a), IL-6 (b), IL-1𝛽 (c), and IL-18 (d) levels were
measured in the kidney of sham-operated rats (sham) and rats that underwent 45min ischemia and 6 h reperfusion in the absence (vehicle)
or presence of EDV (1.2–30𝜇mol/kg, i.v.) or NO-EDV (0.3–6 𝜇mol/kg, i.v.). Data are mean S.E.M. ∗𝑃 < 0.05 versus vehicle.
efficiently attenuated by genetic deficiency or pharmacolog-
ical blockade of iNOS [49–51], while other studies clearly
demonstrated that iNOS-generated NO inhibited ischemic
renal damage [52–54]. This difference may be due to the
different levels of NO production associated with the degree
or method of I/R injury. We demonstrated here that NO-
EDV significantly enhanced eNOS activation and this effect
was associated with reduced iNOS expression in the kidney
of rat that underwent I/R injury in comparison to vehicle-
treated animals. A basal production of NO is necessary
for maintaining an adequate glomerular function, since
the inhibition of NO synthesis may increase both efferent
glomerular arteriolar resistance and glomerular capillary
pressure and induce significant changes in renal histology
[55]. It is noteworthy that the NO-donor moiety is linked
to the radical scavenger EDV which can further prevent the
reaction of NO with the superoxide radical, impeding the
chain of reaction for additional production of ROS such as
hydroxyl radical and hydrogen peroxide, which are known
to contribute to kidney structural and functional alteration
[56]. An additional contribution to the regulatory effects of
NO-EDV on NO pathway may rely on the well-known
NO ability to inhibit the transcription factor NF-𝜅B activity
via several mechanisms [57, 58]. In the present study we
documented a reduced NF-𝜅B nuclear translocation in the
presence ofNO-EDV.As iNOS expression ismainly regulated
by NF-𝜅B [59] and it is attractive to speculate that NO-EDV
might ultimately inhibit I/R-induced iNOS overexpression
throughout a negative feedback-like mechanism. NF-𝜅B
plays also an important role in regulating the transcription
of several other genes, especially those involved in produc-
ing mediators of local and systemic inflammation, such as
cytokines and chemokines. Thus, the reduced activation of
this transcription factor byNO-EDVmay also account for the
decreased production of cytokines in the kidney of animals
that underwent I/R injury. Overall, these effects on selective
signaling pathways may help to explain the lower dose-range
by NO-EDV in comparison with EDV needed to protect
the kidney against I/R injury. Unfortunately, the lack of
direct comparison between NO-EDV and a pharmacological
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strategy relying exclusively on NO supplementation does
not allow us to offer ultimate evidence on the specific
contribution by the NO-donor substructure.
Finally, as AKI has been described as an acute inflam-
matory disease with chronic effects [60], the early inhibition
of inflammatory signaling pathways and related cytokine
production by NO-EDV might account for long-term ben-
eficial effects superior to those achieved by a sole antioxidant
strategy. This is in keeping with recent evidence show-
ing that therapeutic strategies ameliorating endothelial cell
dysfunction and cell infiltration reduce the progression to
renal interstitial fibrosis, a characteristic pathologic change
of chronic kidney disease, developing several days after the
ischemic injury [61]. It has to be stressed, however, that the
lack of long-term evaluation in our study limits this interpre-
tation and the clinical transferability of our findings. Thus,
a further rigorous evaluation of the effects of the tested com-
pound against the functional and histological abnormalities
detectable at longer reperfusion times are warranted to con-
firm and better quantify the NO-donor moiety contribution.
5. Conclusions
In conclusion, we confirmed that EDV exerts protective
effects in an early stage of renal I/R injury and, most notably,
we demonstrated for the first time that the NO-donor moiety
improves EDV efficacy by evoking anti-inflammatory and
endothelial protective effects throughout the modulation
of selective signaling pathways. Overall, our experiments
suggest that the administration of a hybrid compound with
both NO-donor and EDV-related antioxidant properties may
represent a novel pharmacological strategy against I/R injury.
Nevertheless, further data are warranted to assess the stability
performance, long-term effects, safety, and cost requirements
of these hybrid compounds, which can significantly affect the
robustness of the pharmacological approach proposed here.
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